M.A. Davis
University of California, San Diego
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by M.A. Davis.
Gynecologic Oncology | 2014
Kristy K. Ward; Angelica M. Roncancio; Nina R. Shah; M.A. Davis; Cheryl C. Saenz; Michael T. McHale; Steven C. Plaxe
OBJECTIVE To describe the risk of uterine malignancy among women who have had weight loss surgery. METHODS We performed a retrospective cohort study among inpatient admissions of women 18years, or older, registered in the University HealthSystem Consortium (UHC) dataset. The rate of uterine malignancy per hospital admission was calculated. Rates were compared according to whether diagnoses at the time of discharge included history of bariatric surgery, and further, according to whether there was a diagnosis of obesity. RESULTS In admissions of patients who did not have a history of prior bariatric surgery, the rate of uterine malignancy was 599/100,000 (95% CI 590 to 610). Among obese women who had not previously undergone bariatric operations, the rate was 1409/100,000 (95% CI 1380 to 1440). Of women admitted who had a history of bariatric surgery, the rate of uterine malignancy was 408/100,000 (95% CI 370 to 450). The relative risk of uterine malignancy in all admissions for women who had prior bariatric surgery, compared to obese women who had not had bariatric surgery, was 0.29 (95% CI 0.26-0.32). Among women who had bariatric surgery and were not currently obese, the relative risk of uterine malignancy was 0.19 (95% CI 0.17-0.22) compared to obese women who had not undergone bariatric surgery. CONCLUSION A history of bariatric surgery is associated with a 71% reduced risk for uterine malignancy overall, and an 81% reduced risk if normal weight is maintained after surgery. This finding suggests that obesity may be a modifiable risk factor related to development of endometrial cancer.
American Journal of Obstetrics and Gynecology | 2013
Kristy K. Ward; Angelica M. Roncancio; Nina R. Shah; M.A. Davis; Cheryl C. Saenz; Michael T. McHale; Steven C. Plaxe
OBJECTIVE We sought to quantify the relationship of uterine malignancy with body mass index (BMI). STUDY DESIGN The University HealthSystem Consortium database was queried to identify all women undergoing total hysterectomy with a recorded BMI in the overweight and obese categories. Least squares regression was applied to evaluate the association between increasing BMI and the proportion of women with a diagnosis of uterine malignancy. Multivariate binary logistic regression was performed to adjust for other known risk factors including age, race, and other comorbidities. RESULTS There were 6905 women who met inclusion criteria; 1891 (27.4%) of these had uterine malignancy. There is a linear relationship (y = 0.015x - 0.23, R(2) = 0.92) of the probability of uterine malignancy vs BMI. After adjusting for other risk factors, we found that each 1-U increase in BMI was significantly, independently associated with an 11% increase in the proportion of patients diagnosed with uterine malignancy (odds ratio, 1.11; 95% confidence interval, 1.09-1.13; P < .001). CONCLUSION In a population of women undergoing hysterectomy, we observed a linear increase in the frequency of uterine cancer associated with increasing BMI. This finding suggests that even relatively modest weight gain may significantly raise cancer risk. In the United States, the mean BMI for women is 26.5 kg/m(2) and it is estimated that more than half of US women have a BMI within the studys range. Our results could, therefore, be relevant to a majority of the population. The findings could increase popular acceptance of weight management as a key component of general health maintenance and, possibly, as an additional approach to cancer risk reduction.
Gynecologic Oncology | 2014
L.M. Bean; Kristy K. Ward; Nina R. Shah; M.A. Davis; Cheryl C. Saenz; Steven C. Plaxe; Michael T. McHale
Gynecologic Oncology | 2016
K.M. Anderson; M.A. Davis; L.M. Bean; Cheryl C. Saenz; Steven C. Plaxe; Michael T. McHale
Gynecologic Oncology | 2016
L.M. Bean; Kristen M. Anderson; K. Taylor; M.A. Davis; Cheryl C. Saenz; Michael T. McHale; Steven C. Plaxe
Gynecologic Oncology | 2016
L.M. Bean; K. Taylor; K.M. Anderson; M.A. Davis; Cheryl C. Saenz; Steven C. Plaxe; Michael T. McHale
Gynecologic Oncology | 2016
K.M. Anderson; R.T. Hillman; L.M. Bean; M.A. Davis; Cheryl C. Saenz; Michael T. McHale; Steven C. Plaxe
Gynecologic Oncology | 2016
K. Taylor; L.M. Bean; K.M. Anderson; M.A. Davis; Michael T. McHale; Cheryl C. Saenz; Steven C. Plaxe
Gynecologic Oncology | 2015
K.M. Anderson; Nina R. Shah; M.A. Davis; L.M. Bean; Cheryl C. Saenz; Steven C. Plaxe; Michael T. McHale
Gynecologic Oncology | 2015
M.A. Davis; Kristy K. Ward; Nina R. Shah; L.M. Bean; Cheryl C. Saenz; Michael T. McHale; Steven C. Plaxe